Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France

Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France

Linezolid is one of the most effective drugs for treating multidrug-resistant tuberculosis (MDR TB), but adverse effects remain problematic. We evaluated 57 MDR TB patients who had received >1 dose of linezolid during 2011–2016. Overall, patients received 600 mg/day of linezolid for a median of 1...

Full description

Bibliographic Details
Main Authors: Marie Jaspard, Nathalie Butel, Najoua El Helali, Dhiba Marigot-Outtandy, Helene Guillot, Gilles Peytavin, Nicolas Veziris, Bahram Bodaghi, Philippe Flandre, Gregoire Petitjean, Eric Caumes, Valerie Pourcher
Format: Article
Language:English
Published: Centers for Disease Control and Prevention 2020-08-01
Series:Emerging Infectious Diseases
Subjects:
Tuberculosis
MDR-XDR
linezolid
neuropathy
pharmacokinetics
tuberculosis and other mycobacteria
Online Access:https://wwwnc.cdc.gov/eid/article/26/8/19-1499_article

Internet

https://wwwnc.cdc.gov/eid/article/26/8/19-1499_article

Similar Items